New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma. Cholangiocarcinoma is a subtype of bile duct cancer with aggressive behavior and poor prognosis. Despite the low incidence, most patients die from the disease and therefore new effective therapies are urgently needed.